The ideal treatment for stroke, is of course, prevention. This book is dedicated to that premise. To prevent stroke one must be able to identify that portion of the population that is at high risk and to identify factors that contribute to this risk. The remarkable decline in stroke mortality must be related to either a decreased risk for stroke or better treatment. The data suggest that both may be true to some degree. Nevertheless, although better treatment of stroke may have something to do with this decline, the evidence is compelling that recognition, treatment, and altering risk factors to prevent stroke are major reasons. If the purposes of this book are to be accomplished, it is imperative to identify potential risk factors, establish the relative degree of risk, and to remove or treat them appropriately.


Cerebral Infarction Transient Ischemic Attack Lupus Anticoagulant Framingham Study Stroke Incidence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mortality trends-United States, 1986–1988. MMWR. 1989;38:117–118.Google Scholar
  2. 2.
    American Heart Association. Stroke Facts. 1989: p1.Google Scholar
  3. 3.
    Adelman SM. The National Survey of Stroke: economic impact. Stroke. 1981;12(suppl I):169–178.Google Scholar
  4. 4.
    Wolf PA, Kannel WB, Verier J. Current status of risk factors for stroke. In: Barnett HJM, ed. Neurologic Clinics, vol 1. no 1. Philadelphia: W.B. Saunders Company; 1983: pp 317–343.Google Scholar
  5. 5.
    Garraway WM, Whisnant JP, Furlan AJ, et al. The declining incidence of stroke. TV Engl J Med. 1979; 300:449–452.CrossRefGoogle Scholar
  6. 6.
    Dyken ML, Wolf PA, Barnett HJM, et al. Risk factors in stroke: a statement for physicians by the subcommittee on risk factors and stroke of the stroke council. Stroke. 1984;15:1105–1111.CrossRefGoogle Scholar
  7. 7.
    Kannel WB, Wolf PA, McGee DL, et al. Systolic blood pressure, arterial rigidity, and risk of stroke; the Framingham study. JAMA. 1981 ;245:1225–1229.PubMedCrossRefGoogle Scholar
  8. 8.
    Wolf PA. Hypertension as a risk factor for stroke. In: Whisnant JP, Sandok B, eds. Cerebral Vascular Diseases. New York, NY: Grune & Stratton; 1975: p 105.Google Scholar
  9. 9.
    Kannel WB, Wolf PA, Verier J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke: the Framingham study. JAMA. 1970;214:301–310.PubMedCrossRefGoogle Scholar
  10. 10.
    Rutan GH, Kuller LH, Neaton JD, et al. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation. 1988;77:504–514.PubMedCrossRefGoogle Scholar
  11. 11.
    Shimizu Y, Kato H, Lin CH, et al. Relationship between longitudinal changes in blood pressure and stroke incidence. Stroke. 1984;15:839–846.PubMedCrossRefGoogle Scholar
  12. 12.
    Brott T, Thalinger K, Hertzberg F. Hypertension as a risk factor for spontaneous intracerebral hemorrhage. Stroke. 1986;17:1078–1083.PubMedCrossRefGoogle Scholar
  13. 13.
    Sacco RL, Wolf PA, Bharucha NE, et al. Subarachnoid and intracerebral hemorrhage: natural history, prognosis, and precursive factors in the Framingham study. Neurology. 1984;34:847–854.PubMedCrossRefGoogle Scholar
  14. 14.
    Sacco RL, Wolf PA, Kannel WB, et al. Survival and recurrence following stroke: the Framingham study. Stroke. 1982;13:290–295.PubMedCrossRefGoogle Scholar
  15. 15.
    Kannel WB, Thorn TJ. Implications of the recent decline in cardiovascular mortality. Cardiovasc Med. 1979;4:983–997.Google Scholar
  16. 16.
    Carter AB. Hypotensive therapy in stroke survivors. Lancet. 1970; 1:185.Google Scholar
  17. 17.
    Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of the hypertension detection and follow-up program: III. Reduction in stroke incidence among persons with high blood pressure. JAMA. 1982;247:633–638.CrossRefGoogle Scholar
  18. 18.
    Taguchi J, Freis ED. Partial reduction of blood pressure and prevention of complications in hypertension. N Engl J Med. 1978;291:329–331.CrossRefGoogle Scholar
  19. 19.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: I. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028–1034.CrossRefGoogle Scholar
  20. 20.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressures averaging 90 through 114 mm Hg. JAMA. 1970;213:1143–1152.CrossRefGoogle Scholar
  21. 21.
    Ueda K, Omae T, Hasuo Y, et al. Prevalence and long-term prognosis of mild hypertensives and hypertensives in a Japanese community, Hisayama. J Hypertens. 1988;6:981–989.PubMedCrossRefGoogle Scholar
  22. 22.
    Cox JP, O’Brien ET, O’Malley K. Treatment of elderly hypertensives: results and implications of recent trials. J Cardiovasc Pharmacol. 1987; 10 (Suppl 2):S65–70.Google Scholar
  23. 23.
    Samuelsson OG, Wilhelmsen LW, Svardsudd KF, et al. Mortality and morbidity in relation to systolic blood pressure in two populations with different management of hypertension: the study of men born in 1913 and the multifactorial primary prevention trial. J Hypertens. 1987;5:57–66.PubMedCrossRefGoogle Scholar
  24. 24.
    Davidson RA, Caranason GJ. Should the elderly hypertensive be treated? Evidence from clinical trials. Arch Intern Med. 1987;147:1932–1937.CrossRefGoogle Scholar
  25. 25.
    MacMahon S, Cutler JA, Stamler J. Antihypertensive drug treatment. Potential, expected and observed effects on stroke and on coronary heart disease. Hypertension. 1989;13:145–150.CrossRefGoogle Scholar
  26. 26.
    Peart S. Results of MRC (UK) trial of drug therapy for mild hypertension. Clin Invest Med. 1987; 10: 616–620.PubMedGoogle Scholar
  27. 27.
    Doyle AE. The Australian therapeutic trial in mild hypertension. Nephron. 1987;47(Suppl 1): 115 – 119.PubMedCrossRefGoogle Scholar
  28. 28.
    Tuomilehto J, Piha T, Nissinen A, et al. Trends in stroke mortality and in antihypertensive treatment in Finland from 1972 to 1984 with special reference to North Karelia. J Hum Hypertens. 1987; 1: 201–208.PubMedGoogle Scholar
  29. 29.
    Fieschi C, Carolei A, Salvetti M, et al. Systemic hypertension as a treatable risk factor for cerebrovascular disease. Am J Cardiol. 1989;63:19C-21C.CrossRefGoogle Scholar
  30. 30.
    Toole JF, Janeway R, Choi K, et al. Transient ischemic attacks due to atherosclerosis: a prospective study of 160 patients. Arch Neurol. 1975;32: 5–12.PubMedCrossRefGoogle Scholar
  31. 31.
    Knutsen R, Knutsen SF, Curb JD, et al. Predictive value of resting electrocardiograms for 12-year incidence of stroke in the Honolulu Heart Program. Stroke. 1988;19:555–559.PubMedCrossRefGoogle Scholar
  32. 32.
    Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982; 306:1018–1022.PubMedCrossRefGoogle Scholar
  33. 33.
    Wolf PA, Dawber TR, Thomas HE Jr, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke, the Framingham study. Neurology. 1978;28:973–977.PubMedCrossRefGoogle Scholar
  34. 34.
    Davis PH, Dambrosia JM, Schoenberg BS, et al. Risk factors for ischemic stroke: a prospective study in Rochester, Minnesota. Ann Neurol. 1987; 22:319–327.PubMedCrossRefGoogle Scholar
  35. 35.
    Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med. 1987;317:669–674.PubMedCrossRefGoogle Scholar
  36. 36.
    Petersen P, Godtfredsen J. Risk factors for stroke in chronic atrial fibrillation. Eur Heart J. 1988;9: 291–294.PubMedGoogle Scholar
  37. 37.
    Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. Stroke. 1988;19:15–18.PubMedCrossRefGoogle Scholar
  38. 38.
    Asinger RW, Dyken ML, Fisher M, et al. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol. 1989; 46:727–743.CrossRefGoogle Scholar
  39. 39.
    Dyken ML, Conneally M, Haerer AF, et al. Cooperative study of hospital frequency and character of transient ischemic attacks: I. Background, organization, and clinical surgery. JAMA. 1977;237:882–886.PubMedCrossRefGoogle Scholar
  40. 40.
    Levy DE. How transient are transient ischemic attacks? Neurology. 1988;38:674–677.PubMedCrossRefGoogle Scholar
  41. 41.
    Kinkel PR, Kinkel WR, Jacobs L. Nuclear magnetic resonance imaging in patients with stroke. Semin Neurol. 1986;6:43–52.PubMedCrossRefGoogle Scholar
  42. 42.
    Salgado ED, Weinstein M, Furlan AJ, et al. Proton magnetic resonance imaging in ischemic cerebrovascular disease. Ann Neurol. 1986;20: 502–507.PubMedCrossRefGoogle Scholar
  43. 43.
    Schoenberg BS, Schoenberg DG, Pritchard DA, et al. Differential risk factors for complete stroke and transient ischemic attacks (TIA): study of vascular diseases (hypertension, cardiac disease, peripheral vascular disease) and diabetes mellitus. In: Duvoi-sin RC, ed. Transactions of the American Neurological Association, vol 105. New York, NY: Springer Publishing Company; 1980: p 165.Google Scholar
  44. 44.
    Weinfeld FD, ed. The National Survey of Stroke. National Institute of Neurological and Communicative Disorders and Stroke. Stroke. 1981; 12 (suppl): 1–1.Google Scholar
  45. 45.
    Mohr JP, Caplan LR, Melski JW, et al. The Harvard cooperative stroke registry. Neurology. 1978; 28:754–762.PubMedCrossRefGoogle Scholar
  46. 46.
    Whisnant JP. The role of the neurologist in the decline of stroke. Ann Neurol. 1983; 14:1–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Whisnant JP. Epidemilogy of stroke: emphasis on transient cerebral ischemia attacks and hypertension. Stroke. 1974;5:68–70.PubMedCrossRefGoogle Scholar
  48. 48.
    Bousser MG, Eschwege E, Haguenau M, et al. “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke. 1983;14:5–14.PubMedCrossRefGoogle Scholar
  49. 49.
    Canadian Cooperative Stroke Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med. 1978;299:53–59.CrossRefGoogle Scholar
  50. 50.
    Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Stroke. 1977;8:301–316.PubMedCrossRefGoogle Scholar
  51. 51.
    Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Part II: Surgical group. Stroke. 1978;9:309–318.PubMedCrossRefGoogle Scholar
  52. 52.
    Sorenson PS, Pedersen H, Marquardsen J, et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. Stroke. 1983; 14: 15–22.CrossRefGoogle Scholar
  53. 53.
    Swedish Cooperative Study. High-dose acetylsalicylic acid after cerebral infarction. Stroke. 1987; 18:325–334.CrossRefGoogle Scholar
  54. 54.
    The ESPS Group. The European stroke prevention study (ESPS): principal end-points. Lancet. 1987; 2:1351–1354.Google Scholar
  55. 55.
    UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br Med J (Clin Res). 1988;296:316–320.CrossRefGoogle Scholar
  56. 56.
    Ruether R, Dorndorf W. Aspirin in patients with cerebral ischemia and normal angiograms or nonsurgical lesions: the results of a double-blind trial. In: Breddin K, Dorndorf W, Lowe D, et al., eds. Acetylsalicylic Acid in Cerebral Ischemia and Coronary Heart Disease. Stuttgart: Schattauer; 1978: pp 97–106.Google Scholar
  57. 57.
    Dyken ML. Anticoagulant and platelet-antiaggre-gating therapy in stroke and threatened stroke. In: Barnett HJM, ed. Neurologic Clinics, vol 1. no 1. Philadelphia, PA: W.B. Saunders Company; 1983: pp 223–242.Google Scholar
  58. 58.
    Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 1989;1321:501–507.CrossRefGoogle Scholar
  59. 59.
    Gent M, Blakely JA, Easton JD, et al., The CATS Group. The Canadian American Ticlopidine study (CATS) in thromboembolic stroke. Lancet. 1989; 1:1215–1220.PubMedCrossRefGoogle Scholar
  60. 60.
    Dyken ML. Precipitating factors, prognosis, and demography of cerebrovascular disease in an Indiana Community: a review of all patients hospitalized from 1963–1965 with neurologic examination of survivors. Stroke. 1970;1:261–269.PubMedCrossRefGoogle Scholar
  61. 61.
    Paffenbarger RS Jr, Williams JL. Chronic disease in former college students: V. Early precursors of fatal stroke. Am J Public Health. 1967;57:1290–1299.CrossRefGoogle Scholar
  62. 62.
    Wolf PA, DAgostino RB, Kännel WB, et al. Cigarette smoking as a risk factor for stroke: the Framingham study. JAMA. 1988;259:1025–1029.PubMedCrossRefGoogle Scholar
  63. 63.
    Colditz GA, Bonita R, Stampfer MJ, et al. Cigarette smoking and risk of stroke in middle-aged women. N Engl J Med. 1988;318:937–941.PubMedCrossRefGoogle Scholar
  64. 64.
    Menotti A, Mariotti S, Seccareccia S, et al. The 25 year estimated probability of death from some specific causes as a function of twelve risk factors in middle aged men. Eur J Epidemiol. 1988;4: 60–67.PubMedCrossRefGoogle Scholar
  65. 65.
    Boysen G, Nyboe J, Appleyard M, et al. Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke. 1988;19:1345–1353.PubMedCrossRefGoogle Scholar
  66. 66.
    Abbott RD, Yin Y, Reed DM, et al. Risk of stroke in male cigarette smokers. TV Engl J Med. 1986; 315:717–720.CrossRefGoogle Scholar
  67. 67.
    Shinton R, Beevers G. Meta-analysis of relation between ciagarette smoking and stroke. Br Med J. 1989;298:789–794.CrossRefGoogle Scholar
  68. 68.
    Kagan A, Harris BR, Winkelstein W Jr, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics. J Chronic Dis. 1974; 27:345–364.PubMedCrossRefGoogle Scholar
  69. 69.
    Kagan A, Popper JS, Rhoads GG, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: prevalence in stroke. In: Scheinberg P, ed. Cerebrovascular Diseases. New York, NY: Raven Press; 1976: p 267.Google Scholar
  70. 70.
    Klatsky AL, Armstrong MA, Friedman GD. Alcohol use and subsequent cerebrovascular disease hospitalizations. Stroke. 1989;20:741–746.PubMedCrossRefGoogle Scholar
  71. 71.
    Donahue RF, Abbott RD, Reed DM, et al. Alcohol and hemorrhagic stroke. The Honolulu Heart Program. JAMA. 1986;255:2311–2314.PubMedCrossRefGoogle Scholar
  72. 72.
    Stampfer MJ, Colditz GA, Willett WC, et al. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med. 1988;319:267–273.PubMedCrossRefGoogle Scholar
  73. 73.
    Hillbom M, Kaste M. Alcohol intoxication: a risk factor for primary subarachnoid hemorrhage. Neurology. 1982;32:706–711.PubMedCrossRefGoogle Scholar
  74. 74.
    Lee K. Alcoholism and cerebrovascular thrombosis in the young. Acta Neurol Scand. 1979; 59:270.PubMedCrossRefGoogle Scholar
  75. 75.
    Gill JS, Shipley MJ, Hornby RH, et al. A community case-control study of alcohol consumption in stroke. Int J Epidemio. 1988;17:542–547.CrossRefGoogle Scholar
  76. 76.
    Gorelick PB, Rodin MB, Langenberg P, et al. Is acute alcohol ingestion a risk factor for ischemic stroke? Results of a controlled study in middle-aged and elderly stroke patients at three urban medical centers. Stroke. 1987;18:359–364.PubMedCrossRefGoogle Scholar
  77. 77.
    Dintenfass L. Elevation of blood viscosity, aggregation of red cells, haematocrit values and fibrinogen levels with cigarette smokers. Med J Aust. 1975;1:617–620.PubMedGoogle Scholar
  78. 78.
    Ettinger PO, Wu CF, De La Cruz C Jr, et al. Arrhythmias and the “Holiday Heart”: Alcohol-associated cardiac rhythm disorders. Am Heart J. 1978;95:555–562.PubMedCrossRefGoogle Scholar
  79. 79.
    Brust JCM. Stroke and substance abuse. In: Barnett HJM, Mohr JP, Stein BM, et al., eds. Stroke Pathophysiology, Diagnosis and Management, vol 2. New York, NY: Churchill Livingstone; 1986: pp 903–917.Google Scholar
  80. 80.
    Klonoff DC, Andrews BT, Obana WG. Stroke associated with cocaine use. Arch Neurol. 1989; 46:989–993.PubMedCrossRefGoogle Scholar
  81. 81.
    Dyer AR, Stamler J, Paul O, et al. Serum cholesterol and risk of death from cancer and other causes in three Chicago epidemiological studies. J Chronic Dis. 1981;34:249–260.PubMedCrossRefGoogle Scholar
  82. 82.
    Farid NR, Anderson J. Cerebrovascular disease and hyperlipoproteinemia. Lancet. 1972;1:1398–1399.PubMedCrossRefGoogle Scholar
  83. 83.
    Kannel WB. Epidemiology of cerebrovascular disease. In: Russell RWR, ed. Cerebral Arterial Disease. Edinburgh: Churchill Livingstone; 1976: pp 1–23.Google Scholar
  84. 84.
    Mathew NT, Davis D, Meyer JS, et al. Hyperlipoproteinemia in occlusive cerebrovascular disease. JAMA. 1975;232:262–266.PubMedCrossRefGoogle Scholar
  85. 85.
    Kaste M, Koivisto P. Risk of brain infarction in familial hypercholesterolemia. Stroke. 1988; 19: 1097–1100.PubMedCrossRefGoogle Scholar
  86. 86.
    Lapidus L, Bengtsson C, Lindquist O, et al. 1988 Triglycerides—main lipid risk factor for cardiovascular disease in women? Acta Med Scan. 1985; 217:481–489.Google Scholar
  87. 87.
    Kagan A. Popper JS, Rhoads GG, et al. Dietary and other risk factors for stroke in Hawaiian Japanese men. Stroke. 1985;16:390–396.PubMedCrossRefGoogle Scholar
  88. 88.
    Khaw KT, Barrett-Connor E. Dietary potassium and stroke-associated mortality—a 12 years prospective population study. N Engl J Med. 1987;316: 235–240.PubMedCrossRefGoogle Scholar
  89. 89.
    Collaborative Group for the Study of Stroke in Young Women. Oral contraception and increased risk of cerebral ischemia or thrombosis. N Engl J Med. 1973;288:871–878.CrossRefGoogle Scholar
  90. 90.
    Handin RI. Thromboembolic complications of pregnancy and oral contraceptives. Prog Cardiovasc Dis. 1974;16:395–405.PubMedCrossRefGoogle Scholar
  91. 91.
    Layde PM, Beral V, Kay CR. Further analyses of mortality in oral contraceptive users. (Royal College of General Practitioners’ Oral Contraception Study). Lancet. 1981;1:541.Google Scholar
  92. 92.
    Petitti DB, Wingerd J, Pellegrin F, et al. Risk of vascular disease in women: smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA. 1979;242:1150–1154.PubMedCrossRefGoogle Scholar
  93. 93.
    Comer TP, Tuerck DG, Bilas RA, et al. Comparison of strokes in women of childbearing age in Rochester, Minnesota and Bakersfield, California. Angiology. 1975;26:351–355.PubMedCrossRefGoogle Scholar
  94. 94.
    Schoenberg BS, Whisnant JP, Taylor WF, et al. Strokes in women of childbearing age: a population study. Neurology. 1970;20:181–189.PubMedCrossRefGoogle Scholar
  95. 95.
    Shearman RP. Oral contraceptives: where are the excess deaths? Med J Aust. 1981; 1:698.PubMedGoogle Scholar
  96. 96.
    Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med. 1988;319:1313–1317.PubMedCrossRefGoogle Scholar
  97. 97.
    Wiseman RA, MacRae KD. Oral contraceptives and the decline in mortality from circulatory disease. Fertil Steril. 1981;35:277–283.PubMedGoogle Scholar
  98. 98.
    Lidegaard O. Cerebrovascular deaths before and after the appearance of oral contraceptives. Acta Neurol Scand. 1988;75:427–433.CrossRefGoogle Scholar
  99. 99.
    Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking and cardiovascular morbidity in women over 50. N Engl J Med. 1985;313:1038–1043.PubMedCrossRefGoogle Scholar
  100. 100.
    Paganini-Hill A, Ross RI, Henderson BE. Postmenopausal estrogen treatment and stroke: a prospective study. Br Med J (Clin Res). 1988;297:519–522.CrossRefGoogle Scholar
  101. 101.
    Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313:1044–1049.PubMedCrossRefGoogle Scholar
  102. 102.
    Johnson KG, Yano K, Kato H. Cerebral vascular disease in Hiroshima, Japan. Jpn J Chronic Dis. 1967;20:545.CrossRefGoogle Scholar
  103. 103.
    Katsuki S, Omae T, Hirota Y Epidemiological and clinicopathological studies on cerebrovascular disease. Kyushi J Med Sci. 1964; 15:127.Google Scholar
  104. 104.
    Marquardsen J. The natural history of acute cerebrovascular disease: a retrospective study of 769 patients. Acta Neurol Scand. 1969;45(suppl 38): 11.PubMedGoogle Scholar
  105. 105.
    Paffenbarger RS Jr, Laughlin ME, Gima AS, et al. Work activity of longshoremen as related to death from coronary heart disease and stroke. N Engl J Med. 1970;282:1109–1114.PubMedCrossRefGoogle Scholar
  106. 106.
    Miller FD, Reed DM, MacLean CJ. A prospective study of mortality and morbidity among carpenters in the Honolulu Heart Program Cohort. J Occup Med. 1988;30:879–882.PubMedCrossRefGoogle Scholar
  107. 107.
    Kannel WB. Health and obesity: an overview. In: Conn HL Jr, DeFelice EA, Kuo P, eds. Health and Obesity. New York, NY: Raven Press; 1983: p 1.Google Scholar
  108. 108.
    Welin L, Svardsudd K, Wilhelmsen L, et al. Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med. 1987;317:521–526.PubMedCrossRefGoogle Scholar
  109. 109.
    Bengtsson C, Lapidus L, Stendahl C, et al. Hyperuricaemia and risk of cardiovascular disease and overall death: a 12-year follow-up of population study of women in Gothenburg, Sweden. Acta Med Scan. 1988;224:549–555.CrossRefGoogle Scholar
  110. 110.
    Syrjanen J, Valtonen VV, Iivanainen M, et al. Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients. Br Med J Clin Res. 1988; 196:1156–1160.CrossRefGoogle Scholar
  111. 111.
    Syrjanen J, Peltola J, Valtonen V, et al. Dental infections in association with cerebral infarction in young and middle-aged men. J Intern Med. 1989; 225:179–184.PubMedCrossRefGoogle Scholar
  112. 112.
    Boers GH, Smals AG, Trijbels FJ, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709–715.PubMedCrossRefGoogle Scholar
  113. 113.
    Mudd SH. Vascular disease and homocysteine metabolism. Editorial. N Engl J Med. 1985;313: 751–753.PubMedCrossRefGoogle Scholar
  114. 114.
    Brattstrom LE, Israelsson B, Jeppsson JO, et al. Folic acid —an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest. 1988;48: 215–221.PubMedCrossRefGoogle Scholar
  115. 115.
    Robins M, Baum HM. The National Survey of Stroke. Incidence. Stroke. 1981 ;12(suppl): 145–155.Google Scholar
  116. 116.
    Monthly Vital Statistics Report-Final Data From the National Center for Health Statistics. U.S. Department of Health and Human Services, vol. 35, no. 6. September 26, 1986.Google Scholar
  117. 117.
    London WT, Rosenberg SE, Draper JF, et al. The effect of estrogens on atherosclerosis: a postmortem study. Ann Int Med. 1961;55:63.PubMedCrossRefGoogle Scholar
  118. 118.
    Marmorston J. Effect of estrogen treatment in cerebrovascular disease. In: Cerebral Vascular Diseases. New York, NY: Grune & Stratton, 1965: p214.Google Scholar
  119. 119.
    Rivin AU, Dimitroff SP. The incidence and severity of atherosclerosis in estrogen-treated males, and in females with hypoestrogenic or a hyperes-trogenic state. Circulation. 1954;9:533–539.PubMedCrossRefGoogle Scholar
  120. 120.
    Stamler J, Pick R, Katz LN, et al. Effectiveness of estrogens for therapy of myocardial infarction in middle-aged men. JAMA. 1963;183:632–638.PubMedCrossRefGoogle Scholar
  121. 121.
    Veterans Administration Cooperative Study Group. Estrogenic therapy in men with ischemic cerebrovascular disease: effect on recurrent cerebral infarction and survival. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section. Stroke. 1972; 3:427–433.CrossRefGoogle Scholar
  122. 122.
    Heyden S, Heyman A, Camplong L. Mortality patterns among parents of patients with atherosclerotic cerebrovascular disease. J Chronic Dis. 1969; 22:105–110.PubMedCrossRefGoogle Scholar
  123. 123.
    Khaw KT, Barrett-Connor E. Family history of stroke as an independent predictor of ischemic heart disease in men and stroke in women. Am J Epidemiol. 1986;123:59–66.PubMedGoogle Scholar
  124. 124.
    Diaz JF, Hachinski VC, Federson LL, et al. Aggregation of multiple risk factors for stroke in siblings of patients with brain infarction and transient ischemic attacks. Stroke. 1986;17:1239–1242.PubMedCrossRefGoogle Scholar
  125. 125.
    Sprafka JM, Folsom AR, Burke GL, et al. Prevalence of cardiovascular disease risk factors in blacks and whites: the Minnesota Heart Survey. Am J Public Health. 1988;78:1546–1549.PubMedCrossRefGoogle Scholar
  126. 126.
    Friday G, Lai SM, Alter M, et al. Stroke in the Lehigh valley: racial/ethnic differences. Neurology. 1989;39:1165–1168.PubMedCrossRefGoogle Scholar
  127. 127.
    Gillum RF. Stroke in blacks. Stroke. 1988;19:1–9.PubMedCrossRefGoogle Scholar
  128. 128.
    Folsum AR, Gomez-Marin O, Sprafka JM, et al. Trends in cardiovascular risk factors in an urban black population, 1973–74 to 1985: the Minnesota heart survey. Am Heart J. 1987; 114:1199–1205.CrossRefGoogle Scholar
  129. 129.
    Katsuki S, Hirota Y, Akazome T, et al. Epidemiological studies on cerebrovascular diseases in Hisayama, Kyushu Island, Japan: Part I. With particular reference to cardiovascular status. Jpn Heart J. 1964;5:12–36.CrossRefGoogle Scholar
  130. 130.
    Tanaka H, Ueda Y, Hayashi M, et al. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke. 1982; 13:62–73.PubMedCrossRefGoogle Scholar
  131. 131.
    Ueda K, Omae T, Hirota Y, et al. Decreasing trend in incidence and mortality from stroke in Hisayama residents, Japan. Stroke. 1981;12:154–60.PubMedCrossRefGoogle Scholar
  132. 132.
    Worth RM, Kato H, Rhoads GG, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: mortality. Am J Epidemiol. 1975;102:481–490.PubMedGoogle Scholar
  133. 133.
    Sasaki N. The salt factor in apoplexy and hypertension: epidemiological studies in Japan. In: Yamori Y, Lovinberg W, Freis E, eds. Perspectives in Cardiovascular Research. New York, NY: Raven Press; 1979: pp 467–474.Google Scholar
  134. 134.
    Takahashi E, Sasaki N, Takeda J, et al. The geographic distribution of cerebral hemorrhage and hypertension in Japan. Human Biol. 1957;29:139–165.PubMedGoogle Scholar
  135. 135.
    Benfante R, Reed D, Brody J. Biological and social predictors of health in an aging cohort. J Chronic Dis. 1985;38:385–395.PubMedCrossRefGoogle Scholar
  136. 136.
    Shimamoto T, Komachi Y, Inada H, et al. Trends for coronary heart disease and stroke and their risk factors in Japan. Circulation. 1989;79:503–515.PubMedCrossRefGoogle Scholar
  137. 137.
    Tanaka H, Hayashi M, Date C, et al. Epidemiologic studies of stroke in Shibata, a Japanese provincial city: preliminary report on risk factors for cerebral infarction. Stroke. 1985;16:773–780.PubMedCrossRefGoogle Scholar
  138. 138.
    Lin CH, Shimizu Y, Kato H, et al. Cerebrovascular diseases in a fixed population of Hiroshima and Nagasaki, with special reference to relationship between type and risk factors. Stroke. 1984;15:653–660.PubMedCrossRefGoogle Scholar
  139. 139.
    Mitsuyama Y, Thompson LR, Hayashi T, et al. Autopsy study of cerebrovascular disease in Japanese men who lived in Hiroshima, Japan and Honolulu, Hawaii. Stroke. 1979;10:389–395.PubMedCrossRefGoogle Scholar
  140. 140.
    Resch JA, Okabe N, Loewenson RB, et al. Pattern of vessel involvement in cerebral atherosclerosis: a comparative study between a Japanese and Minnesota population. J Atheroscler Res. 1969;9719.Google Scholar
  141. 141.
    Takeya Y, Popper JS, Shimizu Y, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese living in Japan, Hawaii and California: incidence of stroke in Japan and Hawaii. Stroke. 1984;15:15–23.PubMedCrossRefGoogle Scholar
  142. 142.
    Olivares L, Castaneda E, Grife A, et al. Risk factors in stroke: a clinical study in Mexican patients. Stroke. 1973;4:773–781.PubMedCrossRefGoogle Scholar
  143. 143.
    Paffenbarger RS Jr, Wing AL. Chronic disease in former college students. XL early precursors of nonfatal stroke. Am J Epidemiol. 1971;94:524–530.PubMedGoogle Scholar
  144. 144.
    Abbott RD, Donahue RP, MacMahon SW, et al. Diabetes and the risk of stroke: the Honolulu heart program. JAMA. 1987;257:949–952.PubMedCrossRefGoogle Scholar
  145. 145.
    Viitanen M, Eriksson S, Asplund K. Risk of recurrent stroke, myocardial infarction and epilepsy. Eur Neurol. 1988;28:227–231.PubMedCrossRefGoogle Scholar
  146. 146.
    Kannel WB, Gordon T, Wolf PA, et al. Hemoglobin and the risk of cerebral infarction: the Framingham study. Stroke. 1972;3:409–420.PubMedCrossRefGoogle Scholar
  147. 147.
    Pearson TC, Thomas DJ. Physiological and pharmacological factors influencing blood viscosity and cerebral blood flow. In: Tognoni G, Garattini S, eds. Drug Treatment and Prevention in Cerebrovascular Disorders. Amsterdam: Elsevier North Holland; 1979: p 33.Google Scholar
  148. 148.
    Tohgi J, Yamanouchi H, Murakami M, et al. Importance of the hematocrit as a risk factor in cerebral infarction. Stroke. 1978;9:369–374.PubMedCrossRefGoogle Scholar
  149. 149.
    Thomas DJ, Marshall J, Russell RWR, et al. Effect of haematocrit on cerebral blood-flow in man. Lancet. 1977;2:941–943.PubMedCrossRefGoogle Scholar
  150. 150.
    Harrison MJG, Pollock S, Kendall BE, et al. Effect of haematocrit on carotid stenosis and cerebral infarction. Lancet. 1981;2:114.PubMedCrossRefGoogle Scholar
  151. 151.
    LaRue L, Alter M, Lai SM, et al. Acute stroke, hematocrit, and blood pressure. Stroke. 1987; 18: 565–569.PubMedCrossRefGoogle Scholar
  152. 152.
    Ozaita G, Calandre L, Peinado E, et al. Hematocrit and clinical outcome in acute cerebral infarction. Stroke. 1987;18:1166–1168.PubMedCrossRefGoogle Scholar
  153. 153.
    Lowe GDO, Jaap JL, Forbes CD. Relation of atrial fibrillation to acute stroke. Lancet. 1983;1:784–786.PubMedCrossRefGoogle Scholar
  154. 154.
    Scandinavian Stroke Study Group. Multicentre trial of hemodilution in acute ischemic stroke: I. Results in the total patient population. Stroke. 1987; 18: 691–699.CrossRefGoogle Scholar
  155. 155.
    Italian Acute Stroke Study Group. Haemodilution in acute stroke: results of the Italian Haemodilution Trial. Lancet. 1988;1:318–321.Google Scholar
  156. 156.
    Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501–505.PubMedCrossRefGoogle Scholar
  157. 157.
    Wolf PA, Kannel WB, Meeks SL, et al. Fibrinogen as a risk factor for stroke, the Framingham study. Stroke. 1985; 16:139.CrossRefGoogle Scholar
  158. 158.
    Kannel WB, Wolf PA, Castelli WP, et al. Fibrinogen and risk of cardiovascular disease. The Framingham study. JAMA. 1987;258:1183–1186.PubMedCrossRefGoogle Scholar
  159. 159.
    Portnoy BA, Herion JC. Neurological manifestations in sickle-cell disease: with a review of the literature and emphasis on the prevalence of hemiplegia. Ann Intern Med. 1972;76:643–652.PubMedCrossRefGoogle Scholar
  160. 160.
    Kushner M, Simonian N. Lupus anticoagulants, anticardiolipin antibodies, and cerebral ischemia. Stroke. 1989;20:225–229.PubMedCrossRefGoogle Scholar
  161. 161.
    Levine SR, Welch KM. Cerebrovascular ischemia associated with lupus anticoagulant. Stroke. 1987; 18:257–263.PubMedCrossRefGoogle Scholar
  162. 162.
    Young SM, Fisher M, Sigsbee A, et al. Cardiogenic brain embolism and lupus anticoagulant. Ann Neurol. 1989;26:390–392.PubMedCrossRefGoogle Scholar
  163. 163.
    Coull BM, Bourdette DN, Goodnight SH, et al. Multiple cerebral infarctions and dementia associated with anticardiolipin antibodies. Stroke. 1987; 18:1107–1112.PubMedCrossRefGoogle Scholar
  164. 164.
    Levine SR, Kim S, Deegan MJ, et al. Ischemic stroke associated with anticardiolipin antibodies. Stroke. 1987;18:1101–1106.PubMedCrossRefGoogle Scholar
  165. 165.
    Hart RG, Miller VT, Coull BM, et al. Cerebral infarction associated with lupus anticoagulants — preliminary report. Stroke. 1984;15:114–118.PubMedCrossRefGoogle Scholar
  166. 166.
    Heyman A, Wilkinson WE, Heyden S, et al. Risk of stroke in asymptomatic persons with cervical arterial bruits: a population study in Evans County, Georgia. N Engl J Med. 1980;302:838–841.PubMedCrossRefGoogle Scholar
  167. 167.
    Wolf PA, Kannel WB, Sorlie P, et al. Asymptomatic carotid bruit and risk of stroke. The Framingham study. JAMA. 1981;245:1442–1445.PubMedCrossRefGoogle Scholar
  168. 168.
    Conneally PM, Dyken ML, Futty DE, et al. Cooperative study of hospital frequency and character of transient ischemic attacks: VIII. Risk factors. JAMA. 1978;240:742–746.PubMedCrossRefGoogle Scholar
  169. 169.
    Dyken ML. Should the efficacy of carotid endar-terectomy in symptomatic patients be examined in a controlled clinical trial? A study is needed. In: Raichle ME, Powers WJ, eds. Cerebrovascular Diseases. New York, NY: Raven Press; 1987.Google Scholar
  170. 170.
    Dyken ML. Carotid endarterectomy studies: a glimmering of science. Stroke. 1986;17:355–358.PubMedCrossRefGoogle Scholar
  171. 171.
    Meissner I, Wiebers DO, Whisnant JP, et al. The natural history of asymptomatic carotid artery occlusive lesions. Ann Neurol. 1986;20:122.Google Scholar
  172. 172.
    Powers WM, Press GW, Grubb RL Jr, et al. The effect of hemodynamically significant carotid artery disease on the hemodynamic status of the cerebral circulation. Ann Intern Med. 1987; 106: 27–35.PubMedCrossRefGoogle Scholar
  173. 173.
    Powers WJ, Tempel LW, Grubb RL. Influence of cerebral hemodynamics on stroke risk: one-year follow-up of 30 medically treated patients. Ann Neurol. 1989;25:325–330.PubMedCrossRefGoogle Scholar
  174. 174.
    Powers WJ, Grubb RL Jr, Raichle ME. Clinical results of extracranial-intracranial bypass surgery in patients with hemodynamic cerebrovascular disease. J Neurosurg. 1989;70:61–67.PubMedCrossRefGoogle Scholar
  175. 175.
    Bogousslavsky J, Regli F, VanMelle G, et al. Migraine stroke. Neurology. 1988;38:223–227.PubMedCrossRefGoogle Scholar
  176. 176.
    Bogousslavsky J, Regli F. Ischemic stroke in adults younger than 30 years of age: cause and prognosis. Arch Neurol. 1987;44:479–482.PubMedCrossRefGoogle Scholar
  177. 177.
    Rothrock JF, Walicke P, Swenson MR, et al. Migrainous stroke. Arch Neurol. 1988;45:63–67.PubMedCrossRefGoogle Scholar
  178. 178.
    Hilton-Jones D, Warlow CP. The causes of stroke in the young. J Neurol. 1985;232:137–143.PubMedCrossRefGoogle Scholar
  179. 179.
    Chen TC, Leviton A, Edelstein S, et al. Migraine and other diseases in women of reproductive age: The influence of smoking on observed associations. Arch Neurol. 1987;44:1024–1028.PubMedCrossRefGoogle Scholar
  180. 180.
    Pfaffenrath V, Pollmann W, Autenrieth G, et al. Mitral valve prolapse and platelet aggregation in patients with hemiplegic and nonhemiplegic migraine. Acta Neurol Scand. 1987;75:253–257.PubMedCrossRefGoogle Scholar
  181. 181.
    Hogan MJ, Brunet DG, Ford PM, et al. Lupus anticoagulant, antiphospholipid antibodies and migraine. Can J Neurol Sci. 1988;15:420–425.PubMedGoogle Scholar
  182. 182.
    Henrich JB. The association between migraine and cerebral vascular events: an analytical review. J Chronic Dis. 1987;40:329–335.PubMedCrossRefGoogle Scholar
  183. 183.
    Kuller L, Anderson H, Peterson D, et al. Nationwide cerebrovascular disease morbidity study. Stroke. 1970;1:86–99.PubMedCrossRefGoogle Scholar
  184. 184.
    Nefzger MD, Acheson RM, Heyman A. Mortality from stroke among U.S. veterans in Georgia and five western states: I. Study plan and death rates. J Chronic Dis. 1973;26:393–404.PubMedCrossRefGoogle Scholar
  185. 185.
    The WHO MONICA Project. Geographical variation in the major risk factors of coronary heart disease in men and women aged 35–64 years. World Health Stat Q. 1988;41:115–140.Google Scholar
  186. 186.
    Bull GM. Meteorological correlates with myocardial and cerebral infarction and respiratory disease. Br J Prev Soc Med. 1973;27:108–113.PubMedGoogle Scholar
  187. 187.
    Haberman S, Capildeo R, Rose FC. The seasonal variation in mortality from cerebrovascular disease. J Neuro Sci. 1981;52:25.CrossRefGoogle Scholar
  188. 188.
    Knox EG. Meteorological associations of cerebrovascular disease mortality in England and Wales. J Epidemiol Community Health. 1981;35: 220–223.PubMedCrossRefGoogle Scholar
  189. 189.
    Rogot E, Padgett SJ. Associations of coronary and stroke mortality with temperature and snowfall in selected areas of the United States, 1962–1966. Am J Epidemiol. 1976;103:565–575.PubMedGoogle Scholar
  190. 190.
    Berginer VM, Goldsmith J, Vardi H, et al. Clustering of strokes in association with meteorologic factors in the Negev desert of Israel. 1981–1983. Stroke. 1989;20:65–9.PubMedCrossRefGoogle Scholar
  191. 191.
    Biller J, Jones MP, Bruno A, et al. Seasonal variation of stroke —does it exist? Neuro epidemiology. 1988;7:89–98.Google Scholar
  192. 192.
    Marler JR, Price TR, Clark GL, et al. Morning increase in onset of ischemic stroke. Stroke. 1989; 20:473–476.PubMedCrossRefGoogle Scholar
  193. 193.
    Acheson RM, Fairbairn AS. Record linkage in studies of cerebrovascular disease in Oxford, England. Stroke. 1971;2:48–57.PubMedCrossRefGoogle Scholar
  194. 194.
    Acheson RM, Heyman A, Nefzger MD. Mortality from stroke among U.S. veterans in Georgia and five western states: III. Hypertension and demographic characteristics. J Chronic Dis. 1973 ;26: 417–429.CrossRefGoogle Scholar
  195. 195.
    Mann AH, Brennan PJ. Type A behavior score and the incidence of cardiovascular disease: a failure to replicate the claimed associations. J Psychosom Res. 1987;31:685–692.PubMedCrossRefGoogle Scholar
  196. 196.
    Ragland DR, Brand RJ. Type A behavior and mortality from coronary heart disease. N Engl J Med. 1988;318:65–69.PubMedCrossRefGoogle Scholar
  197. 197.
    Eaker ED, Castelli WP. Type A behavior and mortality from coronary disease in the Framingham study. N Engl J Med. 1988;319:1480–1481.PubMedCrossRefGoogle Scholar
  198. 198.
    Kannel WB, Wolf PA. Epidemiology of cerebrovascular disease. In: Ross Russell RW, ed. Vascular Disease of the Central Nervous System. 2nd ed. London: Churchill Livingston; 1983.Google Scholar
  199. 199.
    Longstreth WT Jr, Swanson PD. Oral contraceptives and stroke. Stroke. 1984;15:747–750.PubMedCrossRefGoogle Scholar
  200. 200.
    Sobel E, Alter M, Davanipour Z, et al. Stroke in the Lehigh valley: combined risk factors for recurrent ischemic stroke. Neurology. 1989;39:669–672.PubMedCrossRefGoogle Scholar
  201. 201.
    Miettinen TA, Huttunen JK, Naukkarinen V, et al. Multifactorial primary prevention of cardiovascular diseases in middle-aged men: risk factor changes, incidence, and mortality. JAMA. 1985; 254:2097–2102.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Mark L. Dyken

There are no affiliations available

Personalised recommendations